Pharsight

Furoscix patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272064 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(10 years from now)

US11433044 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(10 years from now)

US9884039 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(10 years from now)

Furoscix is owned by Scpharmaceuticals.

Furoscix contains Furosemide.

Furoscix has a total of 3 drug patents out of which 0 drug patents have expired.

Furoscix was authorised for market use on 07 October, 2022.

Furoscix is available in solution;subcutaneous dosage forms.

Furoscix can be used as use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure.

The generics of Furoscix are possible to be released after 03 April, 2034.

Drugs and Companies using FUROSEMIDE ingredient

Market Authorisation Date: 07 October, 2022

Treatment: Use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

FUROSCIX family patents

Family Patents